PALISADE BIO INC

Palade Bio insider buys signal confidence as the company’s GI drug pipeline moves into phase II—investors should watch regulatory milestones for growth potential.

Palise

Insider buying at Palisade Bio signals confidence amid volatility, yet investors should weigh the company’s GI‑therapeutic potential against its high‑risk profile.

Palaisade Bio insider buy signals confidence in its Phase III Crohn’s drug; watch for FDA filing and market launch in 2026.